Eisai Co., Ltd.

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
6,240 ^JPY	-0.30%		+7.14%	-11.51%

Apr. 24	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	RE
Apr. 23	Alzheimer's drug adoption in US slowed by doctors' skepticism	RE

Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer’s DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022)

March 22, 2022 at 02:10 am EDT

For Print
March 22, 2022

Full text

News release searchSearch

Attachments

Original Link
Original Document
Permalink

Disclaimer

Eisai Co. Ltd. published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 06:09:07 UTC.

Latest news about Eisai Co., Ltd.

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Alzheimer's drug adoption in US slowed by doctors' skepticism	Apr. 23	RE
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	Apr. 01	MT
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	CI
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
Lifenet to Launch Dementia-Focused Insurance Product in April	Mar. 22	MT
Jefferies Adjusts Eisai’s Price Target to 6,300 Yen From 7,500 Yen, Keeps at Hold	Mar. 11	MT
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11	CI
US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel	Mar. 08	RE
Transcript : Eisai Co., Ltd. - Special Call	Mar. 07
Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected	Mar. 07	RE
RMed Online Ltd. announced that it has received funding from Eisai Co., Ltd.	Mar. 05	CI
Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®	Feb. 22	CI
Biogen expects to return to profit growth this year	Feb. 13	RE
Proteins may predict who will get dementia 10 years later, study finds	Feb. 12	RE
Eisai’s Attributable Profit Down 25.6% in Fiscal Nine Months	Feb. 06	MT
Transcript : Eisai Co., Ltd., Q3 2024 Earnings Call, Feb 06, 2024	Feb. 06
Eisai to Roll Out Alzheimer's Drug in China	Feb. 05	MT
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	Feb. 04	RE
Biogen to discontinue development of older Alzheimer's drug Aduhelm	Jan. 31	RE
Eisai's China Arm Seen to Launch Alzheimer's Treatment in July	Jan. 18	MT
European Medicines Regulator to Discuss Marketing Authorization for BioArctic's Alzheimer's Disease Drug	Jan. 11	MT
Biogen, Eisai Receive Approval for Alzheimer's Treatment Leqembi in China	Jan. 10	MT
Eisai Co. Receives Approval in China for Alzheimer’s Drug, Eyes July Sales Launch	Jan. 09	MT

Chart Eisai Co., Ltd.

Duration

Period

More charts

Company Profile

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Eisai Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,240 JPY

Average target price

8,193 JPY

Spread / Average Target

+31.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EISAI CO., LTD.	-11.51%	11.54B
ELI LILLY AND COMPANY	+25.89%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.58%	354B
MERCK & CO., INC.	+20.52%	331B
ABBVIE INC.	+2.78%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-5.91%	144B

Other Pharmaceuticals

Eisai Co., Ltd.

Equities

4523

JP3160400002

Pharmaceuticals

Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer’s DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022)

EPS Revisions